Finoriq research workspace
ARDELYX, INC. (ARDX) Historical Metrics
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the. Review ARDX valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
- Company
- ARDELYX, INC. (ARDX)
- Ticker
- ARDX
- Market Cap
- $1.3B
- Latest Price
- $5.14
- Industry
- Biotech & Pharma
ARDELYX, INC. (ARDX) Current Valuation Metrics
Static valuation preview for ARDELYX, INC. (ARDX). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/SMarket cap divided by latest TTM revenue. | 3.1x | Revenue | TTM Q1 2026 |
| Earnings YieldLatest TTM net income divided by market cap. | -4.4% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -2.7% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 8.92x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.